ampliphi biosciences

kennt wer die aktie hat einige phase 3 produkte biotech.

danke für eure infos  

 

http://messages.finance.yahoo.com/mb/APHB.PK  

ist sehr volatil mm schieben hin und her alle warten auf news.

lasst euch nicht verunsichern meistens zwischen 10000 und 30000 stück am tag.

und dann müssen die wieder covern meistens anfang des jahres april mai geht schon seit 2-3 jahren so. dann 2mio am tag.

fällt dann wieder mit niedrigem volumen mit gelegntlichen upps. usw mal sehen wann die news dieses spielchen durchbrechen.

mfg  

Genzyme AAV success-Ampliphi's AAVs?      1-Mar-12 02:39 pm    
I noticed that last month Genzyme released this rather good news about a Phase 1/2 clinical trial where the subjects' vision was successfully improved with the aid of AAV vectors/gene therapy:

http://www.medscape.com/viewarticle/7582...

Remember that in 2009 Ampliphi (then Targeted Genetics) sold a load of AAV patents and technology to Genzyme:

http://www.in-pharmatechnologist.com/Pro...

And that Ampliphi will benefit as follows:

http://www.ampliphibio.com/index.php/par...

"Under the collaboration, AmpliPhi Biosciences will receive revenue from Genzyme in the event that Genzyme sublicenses the acquired intellectual property within specified time periods, and will receive royalties in the event of commercial sales of products containing AAV vectors covered by the acquired intellectual property."

Question is, are these AAV vectors Ampliphi's?

The possibilities here are yet another reason why imho Ampliphi's valuation is ludicrously low at present given it already effectively has two products ready to start Phase 3 trials and has lots of cash available, equivalent to much of its market cap.  

Nice work!

Last December I was hunting for information on Targeted Genetics’ Choroideraemia Clinical Trials - NCT00643747.

Here's the link to my post and the replies:

http://messages.finance.yahoo.com/Stocks...

There was some success with this process (view the video for a look at ). At this point Ampliphi hasn't come forth with and clarity around ownership or trials status and it's really about time stockholders are updated.

See any info in your research, please post. Thanks in advance.  

New interview with Ampliphi     26-Mar-12 02:41 am    
http://www.eurekalert.org/pub_releases/2...

"Public release date: 25-Mar-2012

Using viruses to beat superbugs
Viruses that can target and destroy bacteria have the potential to be an effective strategy for tackling hard-to-treat bacterial infections. The development of such novel therapies is being accelerated in response to growing antibiotic resistance, says Dr David Harper at the Society for General Microbiology's Spring Conference in Dublin.

Bacteriophages are viruses that can infect bacteria and multiply within them, breaking down the cell and destroying the bacteria - amplifying themselves in the process to deal with more bacteria. They are found everywhere including in river water, soil, sewage and on the human body. Soon after their initial discovery in 1915, bacteriophages were investigated as antibacterial therapeutic agents. A limited understanding of their mode of action meant early work was often unsuccessful and with the advent of the chemical antibiotic era, bacteriophages were passed over as therapeutics.

Dr Harper, Chief Scientific Officer at AmpliPhi Bioscience in Bedfordshire explains why bacteriophages are being revisited as antibacterial agents. "Each bacteriophage is highly specific to a certain type of bacteria and needs the right bacterial host cell in order to multiply. The more bacterial targets there are, the quicker they grow by killing the host cells. Therefore it seems very likely that infections harbouring high numbers of bacteria will benefit most from bacteriophage therapy – for example chronically infected ears, lungs and wounds," he said. "For these types of infection, only a tiny dose of the virus is needed - as small as one thousandth of a millionth of a gram. This can usually be administered directly to the site of infection in a spray, drops or a cream. The major advantage to bacteriophages is that they don't infect human cells so seem likely to be very safe to use."

Increasing resistance to antibiotics has meant that bacterial infections are becoming more and more difficult to treat. With fewer antibiotics available to treat drug-resistant infections, research into bacteriophage therapy has been accelerated. "The rate of new antibiotics coming onto the market does not match the rate of increasing drug-resistance. The need for new approaches to counter such high resistance is both urgent and vital. New approaches will save lives," stressed Dr Harper.

Clinical trials for bacteriophage therapy are now underway. The first clinical trial for safety was reported in 2005 and the results demonstrating the effectiveness of bacteriophage therapy were published in 2009. This clinical trial was conducted by AmpliPhi. The company is planning further clinical trials in conditions where existing antibacterial therapies are not able to help. "With the results of further clinical trials, once regulatory issues are overcome and future investment secured in this area of research, this should lead to the development of novel products suitable for widespread use to tackle bacterial diseases and overcome antibiotic resistance", said Dr Harper."  

http://messages.finance.yahoo.com/Stocks_(A_to_Z)/...;tof=1&frt=2  

http://finance.yahoo.com/mb/APHB/

mfg  

http://finance.yahoo.com/mbview/threadview/...172e5d5a&tls=la,d,0

mfg  

http://finance.yahoo.com/mbview/threadview/...4177f884&tls=la,d,0  

http://finance.yahoo.com/news/...ollaboration-intrexon-121100056.html


p25162 •

Approx. 100,000,000 mil shares, approx. $15 mil market cap., at $0.15.

approx. $15 mil. Market Cap as of today.Based on the press release we just got the updated outstanding share count and Market Cap. Approx. 100,000,000 mil shares,.

I think a fair market cap range today should be at a minimum of $30 mil to $60 mil, or in the $0.30 to $0.60 share price range. Once the Glybera milestone payment is announced (already happened), and royalties revenues start ccming in Q.3 , and a CF Trial partner funded trial announcement the stock could trade in the $1 to $1.50 range.

I'm very encourage by Intrexon novel approach match with APHB phage development.
----------------------------------------
AmpliPhi will issue to Intrexon 24,000,000 shares of its common stock (representing approximately 26% of Ampliphi’s outstanding shares after the issuance). The ECC also includes the potential for development milestones that are payable in equity or cash. In addition, AmpliPhi will pay Intrexon royalties on the net sales of products developed under the ECC Less Less  

More royalties for APHB?

News today - Uniqure are developing a gene therapy for Huntingdons Disease using their AAV platform (presumably derived from APHB/TGEN's technology) and have now received a 2.5m euro grant.


"uniQure B.V., a leader in the field of human gene therapy, today announced
that with its consortium partners it is to receive a EUR 2.5 million Eurostars grant to develop an RNA interference (RNAi) gene therapy for Huntington's disease. The consortium is a pan-European collaboration consisting of uniQure as the coordinator, Lausanne University Hospital, Switzerland, University Medical Center Gottingen, Germany, and Maria Curie-Skłodowska University, Poland.

The program's aim is to develop a gene therapy for the treatment of Huntington's
disease (HD), a rare and devastating neurodegenerative disease caused by
mutations in the Huntingtin (Htt) gene.  

Good PR in the Sunday Times

Huge article in yesterday's Sunday Times in London about routine infections becoming life-threatening, overuse of antibiotics etc.

It talks about the few methods of stopping superbugs - and specifically says:

"■ Invest in research into new treatments and drugs, such as ‘bacteriophage’ viruses that kill bacteria and can be used to sterilise dressings"

APHB are the world leaders in bacteriophages. IMO its time is about to come.

And APHB are recruiting for a Senior Scientist - hopefully this is good news and a sign of confidence:

"AmpliPhi Biosciences is seeking a Senior Scientist to work in the UK laboratory. The post holder will be part of a global team developing bacteriophages (phages) for human and animal antibacterial medicines. We seek a candidate who is motivated by our mission to develop novel healthcare products....

....The post will be based at Colworth Science Park, Sharnbrook, Bedfordshire. Travel to company sites in Sydney, Australia and Richmond, USA may be required."  

l

Big news today - agreement with US Army

News just out....

"AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections
July 01, 2013

AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).

The CRADA will focus on developing and commercializing bacteriophage therapeutics to treat Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa infections. The increasing prevalence of antibiotic-resistant bacteria poses a serious threat to public health and military personnel and is a major problem in hospitals and clinics around the world. The initial indication will be wounds and skin infections from S aureus, which is the leading pathogen in healthcare-associated infections in the United States as a whole, accounting for 30.4% of surgical site infections.

AmpliPhi will retain global regulatory ownership and commercial rights to all products developed as a result of the agreement. USAMRMC will gain access rights to any products developed. WRAIR will be responsible for cGMP production of the lead Staphylococcus product, AmpliPhage-002 for Phase 1 and 2 clinical trials at its Bioproduction Facility. Further details of the agreement including financial terms were not disclosed.

Philip J. Young, CEO of AmpliPhi, said: “This collaboration is a significant partnership for our company. It combines AmpliPhi’s expertise in the discovery and development of bacteriophage-based therapies with the US Army’s scientific and clinical research for the development of phage therapies for treatment of bacterial infections. It will serve to expedite the development, testing and approval of new treatment modalities.  

RICHMOND, Va. & COLWORTH, England & SYDNEY--(BUSINESS WIRE)--

AmpliPhi BioSciences Corp. (APHB), the world leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today the completion of a successful private placement of convertible preferred stock with gross proceeds of $7 million. The financing was led by established life-sciences investors RA Capital Management and Third Security, LLC, with participation from BioScience Managers Pty Ltd.

“We are very pleased to have the support of these outstanding life science investors,” said Philip J. Young, President and Chief Executive Officer of AmpliPhi. "The financing will allow us to more rapidly advance the development and commercialization of a variety of bacteriophage-containing human therapeutics for use in the treatment of bacterial infections.”

Under the terms of the financing, the Company has issued an aggregate amount of approximately 5 million shares of the Company’s newly created Series B convertible preferred stock for an aggregate purchase price of $7 million. Each preferred share is convertible into 10 shares of common stock. Additionally, the Company has issued warrants to purchase an aggregate of up to approximately 17.5 million shares of common stock at an exercise price of $0.14 per share. In connection with the financing, outstanding convertible notes with an aggregate principal value of approximately $6.3 million have converted into approximately 5 million shares of Series B convertible preferred stock, together with warrants to purchase approximately 12.5 million shares of common stock at an exercise price of $0.14 per share.

In conjunction with this financing transaction, Julian P. Kirk, Managing Director of Third Security, LLC, will join AmpliPhi’s Board of Directors. Mr. Jeremy Curnock Cook, Chairman of the Board of Directors, commented, "The addition of Julian is an important milestone in the continued evolution of AmpliPhi. We are excited to be welcoming him to the board and look forward to his guidance through the continued strategic, operational and financial growth of the company." In addition, Dr. Caroline Williams and Mr. Anthony Gellert have resigned from the Board of Directors. “We thank Caroline and Tony for their service and contribution to the progress of the Company,” added Mr. Curnock Cook.

Griffin Securities, Inc. served as lead placement agent and Philip Capital served as co-placement agent to AmpliPhi Biosciences, Inc. in connection with the transaction.

ENDS

About AmpliPhi BioSciences Corp.

AmpliPhi BioSciences Corp. is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics for difficult to treat infectious diseases, which includes treatments for bacterial infections associated with Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus Aureus (MRSA), Escherichia coli (E. coli), and Clostridium difficile (C. difficile). AmpliPhi was created in 2011 through the merger of BioControl Ltd with Targeted Genetics Inc. and subsequent combination with Special Phage Services in 2012. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com

More information about the company is available at www.ampliphibio.com

Forward-looking statements

Statements in this press release about the potential use of bacteriophages to treat bacterial infections and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that such therapies may not be successfully developed, will require extensive and expensive pre-clinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency.  

Excellent news today re Glybera

"July 09, 2013 08:00 ET

uniQure Signs EU Commercialization Agreement With Chiesi Farmaceutici for First Approved Gene Therapy Treatment, and Announces EUR 45 Million (USD 58 Million) in Equity and Collaboration Financing

Partnership With Chiesi Farmaceutici for Commercialization of Glybera and Co-Development of Hemophilia B Gene Therapy in Europe and Certain Other Territories; Conversion of Outstanding Convertible Debt by Coller Capital and Other Investors

AMSTERDAM, THE NETHERLANDS--(Marketwired - Jul 9, 2013) - uniQure B.V., a leader in human gene therapy, today announced it has signed collaboration agreements with Chiesi Famaceutici SpA for the commercialization of Glybera, the first gene therapy to receive regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia B. In connection with this transaction, uniQure has received EUR 17 million (USD 21.8 million) in collaboration financing and EUR 14 million (USD 18 million) in equity financing from Chiesi, and has converted into equity the previously announced EUR 14.1 million (USD 18.1 million) investment led by Coller Capital (London, UK) with participation by existing investors......

.....
The investment from Coller Capital, supplemented by our existing investors, allows us to continue apace with the development of what we believe is the richest and most advanced gene therapy pipeline in the industry. In the next 12-18 months, we anticipate clarifying the path toward an FDA filing for Glybera in the US, reporting results from a Phase I/II study in acute intermittent porphyria, and starting at least two Phase I/II studies for additional pipeline programs."  

New Edison research just out

There's a new catch-up note out from Edison - with a first full note to follow:

Extract:

"Investment summary: Turning a fresh p(h)age

A $7m private placement with RA Capital and Third Security, and a research collaboration with the US army, provide AmpliPhi with fresh impetus in its development of bacteriophages. These deals build on the purchase of Special Phage Services (SPS) last year and a recent strategic collaboration with Intrexon. AmpliPhi is the only company to have completed a controlled Phase I/II study with bacteriophages (naturally-occurring viruses that kill bacteria). The next steps towards technology validation are Phase I and II studies with the US army in 2014 in skin infections due to S Aureus, and a Phase II study to treat Pseudomonas infections in cystic fibrosis (CF)."

"Valuation: Modest $25m EV

We estimate AmpliPhi’s EV at $25m, based on 197m total shares now outstanding and $6.85m net cash at end-Q213. We view this as modest, particularly with regard to the CF opportunity. We will initiate full coverage of AmpliPhi in due course."  

 

 

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89629339

mfg  

Hier gabs aber heavy dilution,hm !  

wie meinst du das? beobachte die firma schon einige zeit aber diesen volumen anstieg in den letzten wochen bzw die vermehrten nachrichten, habe ich noch nicht gesehn. deren produkt pipeline sieht sehr vielversprechend aus. der anstieg müsste nächste woche nachhaltig bis 0,40 0,50 weitergehen ansonsten könnte es mit kleinen umsätzen die nächsten wochen wieder runtergedrückt werden. mal sehen wie es am montag weitergeht.

mfg  

zu gehn  

geil los komm da geht noch was!!!!!